IMUC

ImmunoCellular Therapeutics, Ltd.
IMUC

Overview Fund Activity
Delisted

IMUC was delisted on the 16th of October, 2018.

Back to rankings

17 hedge funds and large institutions have $293K invested in ImmunoCellular Therapeutics, Ltd. in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
17
Holders Change
-1
Holders Change %
-5.56%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
VF
Virtu Financial
New York
+$51.1K
2
Goldman Sachs
Goldman Sachs
New York
+$8K
3
WS
Wedbush Securities
California
+$7.8K

Top Sellers

1
Renaissance Technologies
Renaissance Technologies
New York
-$28.4K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$23K
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$10K
4
UBS Group
UBS Group
Switzerland
-$7.29K
5
TSS
Two Sigma Securities
New York
-$5K
Name Holding Trade Value Shares
Change 		Shares
Change %
Renaissance Technologies
1
Renaissance Technologies
New York
$187K -$28.4K -89,800 -13%
VF
2
Virtu Financial
New York
$61K +$51.1K +162,106 +516%
WS
3
Wedbush Securities
California
$27K +$7.8K +25,000 +41%
Goldman Sachs
4
Goldman Sachs
New York
$8K +$8K +24,166 New
UBS Group
5
UBS Group
Switzerland
$7K -$7.29K -22,496 -51%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$3K – – –
APA
7
American Portfolios Advisors
New York
$2 +$2 +5 New
RE
8
RBC Europe
United Kingdom
$1 – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
– -$23K -62,760 Closed
Bank of New York Mellon
10
Bank of New York Mellon
New York
– -$10K -25,029 Closed
TSS
11
Two Sigma Securities
New York
– -$5K -14,600 Closed
NFG
12
Next Financial Group
Texas
– -$1K -3,000 Closed